op-1250
Small moleculeexperimental
Clinical trial activity
6 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Aug 13, 2020 (NCT04505826)
Timeline
Indications
Mechanism of action
- Estrogen receptorANTAGONIST
Estrogen receptor antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CCCN1CC(Oc2ccc([C@@H]3c4[nH]c5ccccc5c4C[C@@H](C)N3CC(C)(C)F)cc2)C1- Mol. weight
- 449.61 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314475 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07085767 | Phase 3 | Oct 31, 2025 | Novartis, Olema Pharmaceuticals, Inc. |
| NCT06784193 | Phase 1 | Dec 16, 2024 | Olema Pharmaceuticals, Inc. |
| NCT06016738 | Phase 3 | Oct 10, 2023 | Olema Pharmaceuticals, Inc. |
| NCT05508906 | Phase 1 | Aug 31, 2022 | Novartis, Olema Pharmaceuticals, Inc. |
| NCT05266105 | Phase 1 | Dec 10, 2021 | Olema Pharmaceuticals, Inc., Pfizer |
| NCT04505826 | Phase 1/Phase 2 (Phase 2) | Aug 13, 2020 | Olema Pharmaceuticals, Inc. |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Olema Pharmaceuticals, Inc. | For profit | 6 | 6 | 3 | 2020 |
| Novartis | For profit | 2 | 0 | 2 | 2022 |
| Pfizer | For profit | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1